Internal Medicine, Endocrinology, Diabetes, & Metabolism · Cleveland, OH
NPI
1922293547
Since 2007
Specialty
Internal Medicine, Endocrinology, Diabetes, & Metabolism
Code 207RE0101X
Group practices
1
Medicare group memberships
Hospitals
2
Hospital affiliations
9500 Euclid Ave, Desk F-20
Cleveland, OH, 44195
Phone (216) 445-9060
Groups this clinician bills Medicare through
Medicare paid, 2024
$20K
407 services
Medicare patients, 2024
120
Average age 71
Drug cost, 2024
$4.0M
2,896 prescriptions
Company payments, 2025
$213K
From 9 companies
Procedures and visits billed to Original Medicare, 2024
In 2024, the most common Medicare service billed by Kevin M Pantalone was code 99214 (office e&m - established), 178 times for 93 patients. In total Kevin M Pantalone billed 407 services in 15 codes, and Medicare paid $20K.
| Code |
|---|
Official US government data: the national provider registry and Medicare enrollment records, linked by NPI. Last update of this record: 2013-02-25.
| Setting |
|---|
| Services |
|---|
| Patients |
|---|
| Paid per service |
|---|
| Medicare paid |
|---|
| 99214 Office E&M - Established | Office | 178 | 93 | $65.35 | $12K |
| G2211 Visit complexity inherent to evaluation and management associated with medical care services that serve as the continuing focal point for all needed health care services and/or with medical care services that are part of ongoing care related to a patient's | Office | 85 | 61 | $11.90 | $1,012 |
| 95251 Test - Miscellaneous | Office | 69 | 25 | $24.64 | $1,700 |
| 99215 Office E&M - Established | Office | 24 | 17 | $94.51 | $2,268 |
By year: 2022 $15K for 248 services; 2023 $19K for 329 services; 2024 $20K for 407 services.
Medicare prescription drug claims, 2024
In 2024, the drug Kevin M Pantalone prescribed most often to Medicare patients was Ozempic (Semaglutide), with 275 prescriptions and refills. In total Kevin M Pantalone wrote 2,896 Medicare prescriptions that cost $4.0M.
| Drug | Claims | 30-day fills | Patients | Cost |
|---|---|---|---|---|
| Ozempic Semaglutide | 275 | 525 | 62 | $500K |
| Levothyroxine Sodium Generic | 207 | 603 | 59 | $2,395 |
| Metformin Hcl Er Metformin Hcl | 174 | 507 | 58 | $2,861 |
| Glipizide Er Glipizide | 127 | 373 | 34 | $2,550 |
| Mounjaro Tirzepatide | 112 | 137 | 17 | $143K |
| Farxiga Dapagliflozin Propanediol | 99 | 226 | 24 | $126K |
| Atorvastatin Calcium Generic | 97 | 266 | 33 | $1,389 |
| Trulicity Dulaglutide | 80 | 131 | 20 | $124K |
| Lantus Solostar Insulin Glargine,hum.Rec.Anlog | 78 | 213 | 27 | $9,675 |
| Jardiance Empagliflozin | 77 | 213 | 23 | $120K |
| Metformin Hcl Generic | 71 | 210 | 26 | $525 |
| Gabapentin Generic | 65 | 152 | 22 | $2,140 |
| Omnipod 5 Dexg7g6 Pods (Gen 5) Insulin Pump Cart,auto,bt,g6/7 | 54 | 75 | Under 11 | $46K |
| Nano 2nd Gen Pen Needle Pen Needle, Diabetic | 53 | 129 | 19 | $5,288 |
| Rosuvastatin Calcium Generic | 50 | 150 | 16 | $394 |
Brand drugs: 1,263 claims; generic drugs: 1,419 claims.
Money and other things of value reported by the companies
In 2025, drug and medical device companies paid Kevin M Pantalone $213K ($213K in general payments such as food, travel and fees) from 9 companies. The largest payer was Corcept Therapeutics with $102K.
| Company | Payments | Amount |
|---|---|---|
| Corcept Therapeutics CORT | 101 | $102K |
| Novo Nordisk Inc NVO | 60 | $63K |
| Boehringer Ingelheim Pharmaceuticals, Inc. | 12 | $16K |
| Bayer Healthcare Pharmaceuticals Inc. BAYN.DE | 18 | $16K |
| Eli Lilly and Company LLY | 6 | $9,401 |
| Sanofi-Aventis U.S. LLC SNY | 2 | $5,930 |
| Lilly USA, LLC LLY | 6 | $1,138 |
| Xeris Pharmaceuticals, Inc. | 1 | $23.75 |
Official US government data on Original Medicare services, Medicare prescription drug plans and the payments drug and device companies must report. Services with fewer than 11 patients and drugs with fewer than 11 claims are not published. Procedure codes are shown by number with their public category.